Articles

Publications scientifiques 

By

Il faudra bien se rendre à l'évidence

Que les traitements précoces fonctionnent, 
Voici une liste non exhaustive des études scientifiques le prouvant

  1. A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients, Abu Taiub Mohammed Mohiuddin Chowdhury, Mohammad Shahbaz, Md Rezaul Karim, Jahirul Islam, Guo Dan, Shuixiang He
  2. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study, Matthew S Freiberg, et al
  3. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, Reaz, Mahmud, Rahman, Mujibur, Iftikher, Alam, Ahmed, Kazi Gias Uddin, Kabir, A. K. M. Humayon, S. K. Jakaria Been, Mohammad Aftab, Mohammad Monirul, Anindita Das, Mohammad Mahfuzul, Mohammad Abdullah, Mohammad Zaid
  4. The Role of Steroids in the Management of COVID-19 Infection
    Zayar Lin, Wai Hnin Phyu, Zin Hnin Phyu, and Tin Zar Mon
  5. Antithrombotic Therapy to Ameliorate Complications of COVID-19, Brett L Houston et al
  6. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study, Roland Derwand, Martin Scholz, Vladimir Zelenko
  7. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19, Saiful Islam Kha, Sakirul Islam Khan, Chitto Ranjan Debnath, Progga Nanda Nath, Mamun Al Mahtab, Hiroaki Nabeka, Seiji Matsuda, Sheikh Mohammad Fazle Akbar
  8. Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City, Jose Merino, Victor Hugo Borja, Oliva Lopez, José Alfredo Ochoa, Eduardo Clark, Lila Petersen, Saul Caballero
  9. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India, Ravikirti, Roy, R., Pattadar, C., Raj, R., Agarwal, N., Biswas, B., Manjhi, P. K., Rai, D. K., Shyama, Kumar, A., & Sarfaraz, A.
  10. Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers, Simova T., Vekov J., Krasnaliev V., Kornovski P., Bozhinov
  11. Efficacy of a Low Dose of Melatonin… in Hospitalized Patients with COVID-19, GholamHossein Alishiri
  12. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19 Yaseen M. Arabi, George P. Chrousos & G. Umberto Meduri
  13. Early short course corticosteroids in hospitalized patients with COVID-19 (Multi-center quasi-experimental study), Mayur S. Ramesh et al.
  14. Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities, Ahmad I. et al.
  15. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. A Randomized Clinical Trial, Lenze E. et al.
  16. Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study, Di Pierro F. et al.
  17. Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study, Ooi ST et al.
  18. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients, Carlucci P. et al.
  19. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels, Kaufman H. et al.
  20. Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020, Taieb F. et al.
  21. Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities, Ahmad I. et al.
  22. Hydroxychloroquine in Early Treatment of High-Risk COVID-19 Outpatients: Efficacy and Safety Evidence, Risch, Harvey.
  23. Metaanalyses and Aggregated Ivermectin Studies – 1
  24. Metaanalyses and Aggregated Hydroxychloroquin Studies – 1
  25. Metaanalyses and Aggregated Ivermectin Studies – 2

 

Vaccinating Children Means Unnecessary Risks
  1. Deaths by Age U.S. : 0-18, Centers for Disease Control (CDC)
  2. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections, Petra Zimmermann, Nigel Curtis
  3. SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis, Tracy Beth Høeg, Allison Krug, Josh Stevenson, John Mandrola
  4. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units, Lara S. Shekerdemian, MD, MHA; Nabihah R. Mahmood, MD; Katie K. Wolfe, MD; et al.
  5. State-Level Data on COVID-19 child mortality, American Academy of Pediatrics
  6. Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data, C. Smith, D. Odd, R Harwood, J. Ward, M. Linney, M. Clark, D. Hargreaves, SN Ladhani, E. Draper, PJ Davis, SE Kenny, E. Whittaker, K. Luyt, RM Viner, LK Fraser
  7. Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year, JL Ward, R. Harwood, C. Smith, S. Kenny, M. Clark, PJ Davis, ES Draper, D. Hargreaves, S. Ladhani, M. Linney, K. Luyt, S. Turner, E. Whittaker, LK Fraser, RM Viner
  8. Shedding of Infectious SARS-CoV-2 Despite Vaccination, Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Peter J. Halfmann, Hannah E. Segaloff, Anna Kocharian, Kelsey R. Florek, Ryan Westergaard, Allen Bateman, Gunnar E. Jeppson, Yoshihiro Kawaoka, David H. O’Connor, Thomas C. Friedrich, Katarina M. Grande
  9. UK Government Recommendations on Vaccinating Children – Ages 12-15
  10. Comparison of children and young people admitted with SARS-CoV-2 across the UK in the first and second pandemic waves: prospective multicentre observational cohort study, Semple et al.
  11. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum, Stuart P. Weisberg, Thomas J. Connors, Donna L. Farber
  12. Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden, Jonas F. Ludvigsson, Lars Engerström, Charlotta Nordenhäll, Emma Larsson
  13. Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA Vaccine, Ori Snapiri, Chen Rosenberg Danziger, Nina Shirman, Avichai Weissbach, Alexander Lowenthal, Itay Ayalon, Dganit Adam, Havatzelet Yarden-Bilavsky, Efraim Bilavsky
  14. Myocarditis following COVID-19 mRNA vaccination, Saif Abu Mouch, Ariel Roguin, Elias Hellou, Amorina Ishai, Uri Shoshan, Lamis Mahamid, Marwan Zoabi, Marina Aisman, Nimrod Goldschmid, Noa Berar Yanay
  15. Myocarditis following COVID-19 vaccination, Albert, E., Aurigemma, G., Saucedo, J., Gerson, D. S.
  16. Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination, Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S.
  17. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting, Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D.
  18. COVID19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis, Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., Bassareo, P.
  19. Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine, Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M.
  20. Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?, Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A.
  21. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?, Das, B. B., Moskowitz, W. B., Taylor, M. B., Palmer, A.
  22. Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report, Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M.
  23. Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination, Ioannou, A. 
  24. Myocarditis Following COVID-19 Vaccination, Isaak, A., Feisst, A., & Luetkens, J. A.
  25. Myocarditis following COVID-19 vaccination, Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A.
  26. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination, Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J.
  27. Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination, Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y.
  28. Why are we vaccinating children against COVID-19?, Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A.
  29. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination, Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B.
  30. Myocarditis following COVID-19 vaccination – A case series, Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B.
  31. Vaccine advisory committee must be more transparent about decisions, Mahase, E.
  32. COVID vaccines cut the risk of transmitting Delta – but not for long, Mallapaty, S.
  33. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel, Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. 
  34. COVID-19 Vaccine-Induced Thrombosis and Thrombocytopenia: First Confirmed Case from India, Mishra, K., Barki, S., Pattanayak, S., Shyam, M., Sreen, A., Kumar, S., & Kotwal, J.
  35. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series, Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R.
  36. A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products, Rose, J., & McCullough, P. A.
  37. Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine, Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E.
  38. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization, Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R.

 

COVID-Recovered Immunity is Durable
  1. One-year sustained cellular and humoral immunities of COVID-19 convalescents, Jie Zhang, Hao Lin, Beiwei Ye, Min Zhao, Jianbo Zhan, et al.
  2. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections, Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon.
  3. Shedding of Infectious SARS-CoV-2 Despite Vaccination, Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Gunnar E. Jeppson, David H. O’Connor, Thomas C. Friedrich, Katarina M. Grande
  4. Necessity of COVID-19 vaccination in previously infected individuals, Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, Paul Terpeluk, Steven M. Gordon
  5. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection, Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen.
  6. Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection, Ellie Ivanova, Joseph Devlin, et al.
  7. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans, Jackson S. Turner, Wooseob Kim, Elizaveta Kalaidina, Charles W. Goss, Adriana M. Rauseo, Aaron J. Schmitz, Lena Hansen, Alem Haile, Michael K. Klebert, Iskra Pusic, Jane A. O’Halloran, Rachel M. Presti, Ali H. Ellebedy.
  8. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells, Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, Julie Czartoski, Lilin Lai, Grace Mantus, Carson Norwood, Lindsay E. Nyhoff, Venkata Viswanadh Edara, et al.
  9. Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously infected or vaccinated employees, N Kojima, A Roshani, M Brobeck, A Baca, JD Klausner
  10. Single cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine, Suhas Sureshchandra, Sloan A. Lewis, Brianna Doratt, Allen Jankeel, Izabela Ibraim, Ilhem Messaoudi
  11. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Jennifer M. Dan, Jose Mateus, Yu Kato, Kathryn M. Hastie, et al.
  12. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status, Jason Neidleman, Xiaoyu Luo, Matthew McGregor, Guorui Xie, Victoria Murray, Warner C. Greene, Sulggi A. Lee, Nadia R. Roan.
  13. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection, Anu Haveri, Nina Ekström, Anna Solastie, Camilla Virta, Pamela Österlund, Elina Isosaari, Hanna Nohynek, Arto A. Palmu, Merit Melin.
  14. Quantifying the risk of SARS‐CoV‐2 reinfection over time, Eamon O Murchu, Paula Byrne, Paul G. Carty, et al.
  15. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy, Laith J. Abu-Raddad, Hiam Chemaitelly, Peter Coyle, Joel A. Malek.
  16. Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants, Bijaya Kumar Mishra, Debdutta Bhattacharya, Jaya Singh Kshatri, Sanghamitra Pati
  17. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel, Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert, et al.
  18. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection, Asgar Ansari, Rakesh Arya, Shilpa Sachan, Someshwar Nath Jha, Anurag Kalia, Anupam Lall, Alessandro Sette, et al.
  19. Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2, Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, et al.
  20. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells, Jae Hyung Jung, Min-Seok Rha, Moa Sa, Hee Kyoung Choi, Ji Hoon Jeon, et al, Nature Communications.
  21. Antibody Evolution after SARS-CoV-2 mRNA Vaccination, Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew, Zijun Wang, et al.
  22. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals, Carmen Camara, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados. et al.
  23. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population, ​​Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al.
  24. SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands, Maria Skaalum Petersen, Cecilie Bo Hansen, Marnar Fríheim Kristiansen, et al.
  25. Secondary household transmission of SARS-CoV-2 among children and adolescents: clinical and epidemiological aspects, Afonso, E. T., Marques, S. M., Costa, L. D. C., Fortes, P. M., Peixoto, F., Bichuetti-Silva, D. C., . . . Guimaraes, R. A.
  26. The role of children and adolescents in the transmission of SARS-CoV-2 virus within family clusters: A large population study from Oman, Alqayoudhi, A., Al Manji, A., Al Khalili, S., Al Maani, A., Alkindi, H., Alyaquobi, F., . . . Al-Abri, S.
  27. A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir, Leung, Y. H., Li, M. P., & Chuang, S. K.
  28. Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate, Madewell, Z. J., Yang, Y., Longini, I. M., Jr., Halloran, M. E., & Dean, N. E.
  29. Can children of the Sputni k V vaccine recipients become symptomatic?, Mehraeen, E., SeyedAlinaghi, S., & Karimi, A. 

Source: